EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Bridging the evidence gap in isolated proctitis: real-world evidence on medical therapies for isolated proctitis—a nation-wide analysis using data of 8346 patients from UK IBD BioResource

Kaung Yan, Sudheer Kumar Vuyyuru, Shellie Radford, Adam Taylor, Burak Sahin, Bamidele Famokunwa, Gordon W Moran

Crohn’s & Colitis 360 · 2026-10-05 · 8 (4)

DOI: 10.1093/crocol/otag118 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Isolated proctitis (IP) affects a third of patients with ulcerative colitis. The long-term effectiveness of medical therapies in IP is still unclear. Objective To assess the effectiveness of medical therapies in IP. Design A retrospective observational cohort study using data from the NIHR IBD BioResource registered between April 4, 2016, and January 3, 2025. Results A total of 8346 patients with IP were included. The probability of treatment escalation from 5-aminosalicylates (5-ASAs) was 11.1%, 21.5%, and 27.3% at 1, 3, and 5 years respectively. Age onset >40 years was associated with a lower risk (hazard ratio [HR] = 0.552, 95% confidence interval [CI]: 0.491-0.621) and presence of extra-intestinal manifestations (EIMs) associated with a higher risk (HR = 1.701, 95% CI: 1.432-2.020) of treatment escalation. The probability of treatment escalation from thiopurines was 14%, 24.4%, and 30.8% at 1, 3, and 5 years respectively. Montreal classification A3 (HR = 0.707, 95% CI: 0.597-0.836) and longer disease duration (HR = 0.983, 95% CI: 0.972-0.995) were associated with a lower risk, while co-diagnosis of EIM indicated a higher risk (HR = 1.513, 95% CI: 1.209-1.894) of treatment escalation. Compared to infliximab, adalimumab (odds ratio [OR] 0.537, 95% CI: 0.416-0.692) and golimumab (OR 0.361, 95% CI: 0.206-0.618) were associated with reduced odds, while anti-integrin exposure was associated with an increased odds of treatment response (OR 2.033, 95% CI: 1.529-2.720). Conclusion Among the available advanced therapies evaluated, anti-integrin therapy was associated with the highest treatment persistence and response rates in this real-world cohort of IP. Further clinical trials are warranted in IP.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →